The summer slump wore off in September with over 50 Boston startups raising north of a billion dollars in venture funding, including Platelet BioGenesis. Read more >>
The Department of Health and Human Services (HHS) has earmarked funds to aid the development of new technology that could bolster emergency preparedness by producing platelets outside the human body. If the two-year, $4.9 million agreement between HHS Biomedical Advanced Research and Development Authority (BARDA) and Platelet BioGenesis, Inc. (PBG) of Cambridge, Mass., produces the desired results, the technology would improve emergency preparedness by making additional blood products available to save lives during a radiological or nuclear emergency. Read […]
Boston-based Wasabi Technologies, Inc. has scored a partnership and an investment that will pave the cloud storage provider’s way to the Japanese market in a deal that serial entrepreneur and CEO David Friend called “the most important business deal we’ve done since starting the company.” Read more >>
Platelet BioGenesis Receives $56 Million Contract from the Biomedical Advanced Research and Development Authority (BARDA) to Develop Human Stem Cell-Derived Platelets as a Medical Countermeasure to Radiological and Nuclear Exposure. Read more >>
Platelet BioGenesis Inc. said Sept. 9 that it raised more than $26 million in a Series A round co-led by Ziff Capital Partners and Qiming Venture Partners USA. Read more >>
Platelet BioGenesis, Inc. (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics, today announced that it has signed a lease for 18,000 square feet of lab space at 65 Grove Street in the emerging biotech hotbed of Watertown, Mass. Read more >>
Platelet BioGenesis (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics, announced today the hiring of Sam Rasty, Ph.D., as President and CEO. Read more >>
Another summer starts with a bang for Boston startups, which raised over $500 million in June. Read more >>
Platelet BioGenesis, the leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics, announced today the addition of Dr. Richard Murray, president and CEO of Jounce Therapeutics, to its board of directors. Read more >>
The polar vortex that brought bone-chilling temperatures to much of the United States earlier this winter highlighted a near constant concern – an inadequate supply of platelets at blood centers across the country. Read more >>
